Tuberculose multirresistente: a 3.º pandemia?
Palavras-chave:
VIH, tuberculose, multirresistência, transmissão nosocomialResumo
Os autores descrevem a sua experiência re cente com tuberculose resistente e multirresistente, no contexto da infecção pelo vírus da imunodeficiência humana. Chamam em particular a atenção para as dimensões e gravidade desta problemática, nas instituições e na Saúde Pública.
Downloads
Referências
Hannan M, Yates M, Gascoyne, Hinzi D et al. From Lisbon to London: the molecular epidemiology, investigations and infection control aspects of an out break of multidrug resistant tuberculosis in a London teaching hospital. - Abst. em 17th National Congress of the European Society of Micro biology, Paris, Junho l 996, pág. 46.
Easterhook P. Bell A, Hannan M et al. Nosocomial outbreak of multidrug resistant tuberculosis in a London HIV unit: out break investigation and clinical follow-up. Abst. em XI International Conference on Aids, Vancouver. July 10, 1996, pág. 25.
Hannan M. Bell A, Gascoyne, Binzi D et al. An outbreak of multidrug resistam tuberculosis ( MDRT) in a London teaching hospital HIV unit: outbreak investigations, infection control issues and molecular epidemiology. Abst. 7th International Congress for Infectious Diseases, Hong - Kong, June 10 - 13, 1996, pág. 212.
Nardell E and Brickner P. Tuherculosis in New York City - focal transmission of na often fatal disease. JAMA 1996; 276( 15): 1259 - 1260.
Frieden T, Sherman L et al. A multi-institutional outbreak of highly drug-resistant tuberculosis - epidemiology and clinical outcomes. JAMA 1996; 27605): 1259-1260.
Couldwell DL, Dore G et ai. Nosocomial outbreak of tuberculosis in na outpatient HIV treatment room. AIDS 1996; 10(5): 521-525.
Maltez F, Peres H, Machado J. et al. Multidrug resistant tuberculosis and HIV infection. Abst. em 7th International Congress for lnfectious Diseases, Hong-Kong,June 10-13, 1996, pág. 61.
Maltez F. MachadoJ, Peres H, Morgado A, Proença R. Tuherculose multiresistente e infeoção pelo VIH. Abst. em III Congresso Nacional sobre Sida, Porto, 7 - 10 Maio, 1997, pág. 48.
Antunes ML, Antunes FA. The tuberculosis situation in Portugal: a historical perspective to 1994. European communicable disease hulletin. Vol I, nª 3 September 1996.
Sudre P, Hirschel B, Gatel J et al. Tuberculosis among Europe an patient with the acquired immune deficiency syndrome. Tubercle and Lung disease 1996; 77: 322-328.
Raviglione M, Snider E, Kochi A. Global Epidemiology of tuberculosis - Morbiclity and Mortality of a worlwide epidemie. ]AMA 1995; 273 (53) 220 - 226.
OMS. Tuberculosis as an Aids-defining disease in Europe - HIV/ Aids Surveillance in Europe, n" 46, June 1995.
OMS - HIV testing and Surveillance among tuberculosis patients and tuberculosis prevention in HIV infected persons in Europe - HIV/Aids Surveillance in Europe, nº 46, June 1995
Wenger P. OnenJ, Hreeden A, Orfas D, Beck-Sague C, Jarvis W. Control of nosocomial transmission of multidrug resistant Mycobacterium tuberculosis among healthcare workers and HIV infected patients. Lancet 1995; 345: 235 - 240.
From CDC Tuberculosis Morhidity - United Stales, 1996. JAMA 1996: 275 (21 ): 1625- 1630.
Culliton B. Drug resistant TB may bring epidemie. Nature 1992: 356: 473
Bates. J, Nardell I. lnstitutional control measures for tuberculosis in the era of multidrug resistance. Chest 1995. 108: 1690-1710.
Maloney S. Pierson M, Gordon M, Del Castillo R. Boyle J, Jarvis W. Efficacy of control measures in preventing nosocomial transmission of multidrug - resistant tuberculosis of patients and Health care workers. Ann Intern Med 1995; 122: 90 - 95
Jarvis W, Bolyard F, Bozzi C and al. Respirators, recomendations and regulations: the controversy surrounding protection of health care workers from tuberculosis. An lntern Medicine 1995; 122(2): 142- 146.
Brubacher J and Hoffman R. Hazards of ultraviolet lighting used for tuberculosis control. Chest 1996; 109 ( 2): 582-583
National Action Plan to combat Multidrug resistant tuberculosis. MMWR 1992: 41 - no RR - 11
Rastogi N. Emergence of multiple drug resistant tuberculosis: fundamental and applied research aspects, global issues and current strategies. Res Microbiolog 1993; 144, 103 - 158.
De Cock K, Wilkinson D. Tuberculosis control in resource - poor countries: alternative approaches in the era of HIV. Lancet 1995: 346: 675 - 677.
De Cock K, Grant A, Porter J. Preventive therapy for tuberculosis in HIV infected persons: international recommendations. research. and practice. Lancet l 995: 545: 833-836
Haas C, Le Dinh C. Lowenstein W, Durand H. La tuberculose d:ms un service de médicine interne parisien - 50 ohservations. l'resse Médicale 1995: 24(:19): 1911.
Chaulk C. Chaisson R, Lewis J, Rizzo R. - Treating Multidrug resistant tuberculosis, compliance and side efects. JAMA 1994; 271(2):101- 104.
Meeting the challenge of multidrug - resistant tuberculosis: Summary of a Conference. MMWR, June 19. 1992. Vol. 41. NºRR-11.
Rodrigues L. BCG revacination against tuberculosis. Lancet 1996: 348 611.
Fox J. Coalition reacts to surge of Drug - resistant Tl:l. ASM news 1992:'i8(3): 135 - 1.39.
Brausch L, and Bass .J. The treatment of tuberculosis. Medical Clinics of North America 1993; 77(6): 1277 - 1288.
Pozsik C. Compliance with tuberculosis therapy Medical Clinics of North America 1993; 77(6):1289 - 1501.
From CDC - Tuberculosis Morbidity - United States. 1994..JAMA 1995; 274(10): 788 - 789.
Rom WN, Garay SM. Tuberculosis - Little Brown Company. ed. 1996
Ficheiros Adicionais
Publicado
Como Citar
Edição
Secção
Licença
Este trabalho encontra-se publicado com a Licença Internacional Creative Commons Atribuição 4.0.
Direitos de Autor (c) 2023 Medicina Interna
Acesso livre
